(MNGG) Buys Back Debt to Avoid Dilution

(OMEX) HMS Victory (1744) Shipwreck Project Receives Approval From UK Ministry of Defence

Odyssey Marine Exploration to Conduct Operations as Exclusive Archaeological Contractor

TAMPA, Fla., Oct. 24, 2014  — Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), a pioneer in the field of deep-ocean exploration, welcomes today’s statement by the United Kingdom’s Secretary of State for Defence giving consent to proceed with the archaeological investigation and recovery of at-risk artifacts from the HMS Victory (1744) wreck site in accordance with the project design that has been approved by the UK Ministry of Defence (MOD) and Department for Culture Media & Sport (DCMS).

In 2008, Odyssey discovered the shipwreck of HMS Victory (lost 1744) and with the permission of the MOD recovered two cannon to aid positive identification of the shipwreck. The MOD and the DCMS held a joint public consultation on options for the management of the site. In January 2012, a deed of gift transferred the Victory (1744) and associated materials belonging to the Crown to the Maritime Heritage Foundation (MHF), a UK charity. The MHF will next submit the necessary application to the UK Marine Management Organisation to allow operations to begin.

As the exclusive archaeological contractor to the MHF, Odyssey will undertake the activities as outlined in the approved project design, including recording, documentation, conservation and publication. All recovered artifacts will be declared to the Receiver of Wreck in accordance with UK legislation.

“We are looking forward to sharing the progress of this exciting archaeological project and the stories told by the recovered artifacts with the public,” said Lord Lingfield, chairman of the Maritime Heritage Foundation. “HMS Victory is the only wreck of a first-rate English warship discovered underwater anywhere in the world. Odyssey’s archaeological experience with this shipwreck, as well as with many other projects throughout the world, gives us great confidence this important project will be conducted to the highest standards.”

Odyssey president and CEO Mark Gordon commented, “This is an exemplary project for Odyssey that can demonstrate how cooperation between the public and private sectors can benefit business, the government and the public. We are committed to conducting this archaeological project with the greatest of care and concern as we utilize advanced technology, defining procedures, and experts for recording, documentation, recovery, conservation and publication.”

About HMS Victory

The predecessor to Nelson’s favorite warship, HMS Victory was launched in 1737 and later became the flagship of the Channel Fleet. She was lost less than a decade later during a violent storm in October 1744. The Victory is unique as the only scientifically-studied wreck of a first-rate English warship found in the world’s oceans.

Between February and August 2012, Odyssey conducted, on behalf of the Maritime Heritage Foundation, a comprehensive non-disturbance survey that completed the non-disturbance sections (phases 1-2) of the project design. The wide ranging initiatives applied included side-scan and multibeam sonar, production of two photomosaics, the recording of all surface features, remote geophysical sensing for ferrous (FADE), non-ferrous (TSS) and other sub-bottom imaging anomalies (SBI), and an environmental and marine biological site assessment contracted to the University of St. Andrews, Scotland. Three sacrificial frames containing metal and wood samples were buried offsite as part of an environmental studies program.

Five papers detailing this non-disturbance work have been published, including ‘HMS Victory (Site 25C). Preliminary Results of the Non-Disturbance Shipwreck Survey, 2012.‘ These scientific papers, as well as eight others related to Victory, are available at www.victory1744.org, a website dedicated to Victory that includes a unique virtual dive trail.

About the Maritime Heritage Foundation

The Maritime Heritage Foundation is a registered charity founded in April 2011 by its chairman, Lord Lingfield. The Foundation’s mission is to educate the public about maritime heritage. The Victory 1744 Project is intended to further that mission by conducting an archaeological excavation of the shipwreck, recovering, conserving and studying cultural heritage associated with the shipwreck, and sharing the information and recovered artifacts with the public through exhibits, publications, websites and educational programmes. The Maritime Heritage Foundation is advised by its Scientific Advisory Committee chaired by marine archaeologist, Dr. Margaret Rule. The Foundation has selected Odyssey Marine Exploration to serve as exclusive archaeological contractor for the project and Wreck Watch International to serve as archaeological consultant.

About Odyssey Marine Exploration

Odyssey Marine Exploration, Inc. (Nasdaq:OMEX) is engaged in deep-ocean exploration using innovative methods and state of-the-art technology. Odyssey has surveyed and mapped more than 26,000 square miles of seabed and spent more than 15,000 hours diving on shipwreck sites using advanced robotic technology. The company has discovered hundreds of shipwrecks ranging from fifth-century BC Punic sites to German U-boats and Colonial warships.

Odyssey has published 43 archaeological and scientific papers available online and in four volumes of hardbound Oceans Odyssey books. More than 2 million people have been educated and entertained by Odyssey’s traveling exhibit, which features more than 500 artifacts combined with shipwreck history. Odyssey’s finds are also available globally at OdysseysVirtualMuseum.com. Odyssey’s work has been featured in more than 16 hours of prime-time TV programming on the Discovery Channel, National Geographic programming on PBS, NBC, and MSNBC, as well as National Geographic magazine and other national publications.

For additional details about Odyssey, visit www.odysseymarine.com. You can also follow the company on Facebook (www.facebook.com/OdysseyMarine) and Twitter (@OdysseyMarine).

Important Cautions Regarding Forward Looking Information     

Odyssey Marine Exploration believes the information set forth in this Press Release may include “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in “Risk Factors” in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the Securities and Exchange Commission on March 17, 2014. The financial and operating projections, as well as estimates of mining assets, are based solely on the assumptions developed by Odyssey that it believes are reasonable based upon information available to Odyssey as of the date of this release. All projections and estimates are subject to material uncertainties, and should not be viewed as a prediction or an assurance of actual future performance. The validity and accuracy of Odyssey’s projections will depend upon unpredictable future events, many of which are beyond Odyssey’s control and, accordingly, no assurance can be given that Odyssey’s assumptions will prove true or that its projected results will be achieved.

CONTACT: MEDIA CONTACTS:
         Liz Shows
         Odyssey Marine Exploration, Inc.
         (813) 876-1776 x 2335
         lshows@odysseymarine.com

         INVESTOR RELATIONS CONTACT:
         Ron Both
         Liolios Group, Inc.
         (949) 574-3860
         OMEX@liolios.com

(CANV) CEO Releases Letter to Stockholders/Customers Rebuffing Project CBD

LAS VEGAS, Oct. 24, 2014  — CannaVEST Corp. (OTC:CANV), a leading manufacturer and distributor of hemp and cannabidiol (CBD) based products, released a letter from Michael Mona, Jr., Chief Executive Officer, to stockholders and customers regarding a recent report issued by Project CBD:

Dear Stockholders and Customers,

First, thank you for your continued support of and belief in our company. As you may be aware, on October 14, 2014, Project CBD, an organization claiming to be an educational service on the medical utility of the cannabis plant, issued a “special report” titled Hemp Oil Hustlers. In the report, Project CBD makes numerous allegations against individuals and companies in the CBD industry who are not involved with or related to our company. However, of particular concern are the allegations and statements of purported fact concerning the quality and safety of our products.

We owe it to our stockholders and customers to respond to such allegations. The claims disparaging our products are based on scientific inconsistencies, critical flaws in the methodology used to perform tests and false data. Our industry as a whole is subject to numerous attacks, and typically we do not merit such attacks with a response. In this instance, where the quality and safety of our products is attacked, we owe it to our customers and stockholders to respond.

Our methods for processing our hemp oil are expertly controlled from seed to sale. We have invested substantial effort and capital in establishing a world-class research laboratory and processing facility to ensure that our processes for purifying and processing cannabidiol (CBD) exceed all applicable standards. Our lab has achieved purification in excess of 97% on natural (non-synthetic) hemp-based CBD, and our processes and the efforts of our scientific team should be applauded and not disparaged.

With regard to the specific allegations made by Project CBD:

1. Residual Solvents and Heavy Metals – We do not use solvents in our extraction process.  However, the Project CBD report claims that two of the five samples of RSHO tested positive for residual solvents. The Report states “these are all class one solvents, the most dangerous and toxic class of solvents.” First, the solvents identified by Project CBD in the report (hexane, pentane, butane and ethyl acetate) are, in fact, not Class I solvents as defined by the United States Pharmacopia (USP). The identified solvents are either Class II or Class III solvents, and the USP has set acceptable exposure limits for Class II and Class III compounds.With respect to heavy metals, our products have, without exception, tested below the practical quantitation limits for the industry standard ICP-MS method as set forth in Steep Hill’s monograph titled, “Testing Cannabis for Contaminants.” Quite simply our products fall safely in line with the applicable standards, and the Project CBD report is uninformed and just plain wrong.
2. Testing Methods – In addition, the conclusions reported as fact by Project CBD are based on suspect methods. First, Project CBD concedes its sample batches had no chain of custody controls. The samples (allegedly) tested by Project CBD were obtained from third parties. Also, the laboratory used by Project CBD (Flora Research Laboratories) had critical flaws in its methodology – flaws that would prevent the release of data by any reputable, unbiased lab. Specifically, the analysis performed by Flora Research confirmed there were major residue impurities on their injection needle that would lead to carryover between samples. Flora Research also employed shoddy procedures relating to the wash out of nonpolar hemp oil from their needle, which would not dissolve the hemp oil matrix.Based on the testing methods utilized by Flora Research, and what is likely a bias based on its relationships with other CBD suppliers, Project CBD’s data should be disregarded. Although written in a manner to suggest it is objective journalism, the Report should be read for what it is – an effort to discredit our company for the benefit of its competitors.

We have asked the Director of Project CBD, Martin A. Lee, to work with us to vet his conclusions and statements in the interest of ensuring the public has accurate and reliable data concerning our products. Mr. Lee has accepted our invitation and we plan to educate Mr. Lee on our processing methods and protocols.  We also will work with Project CBD to provide reliable and accurate test results.  Ultimately, we are confident Project CBD will agree its report is fatally flawed as it relates to its conclusions about our products.  We look forward to working with Project CBD, because we are confident our processes and end products are the highest quality in the world.

My intention with this letter is to ensure our stockholders and our customers have accurate data concerning the viability and safety of our products. We stand behind our processes and procedures, and we are proud of what we have accomplished to date. We continue to work hard to become world’s largest – and most respected – developer of CBD-based products.

Michael Mona, Jr.
CEO
CannaVEST Corp.

About CannaVEST Corp.

CannaVEST Corp. (OTCBB:CANV), based in Las Vegas, Nevada, focuses on the procurement and wholesale of the hemp plant extract cannabidiol (CBD), and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. CannaVEST resells raw industrial hemp product to third parties, acquired through supply relationships in Europe. Additional information is available from OTCMarkets.com or by visiting www.cannavest.com.
CannaVEST Corp.’s subsidiaries include CannaVest Laboratories, LLC (www.CannaVestLabs.com), which facilitates cutting edge research and develops nutraceutical and food products, containing cannabidiol (CBD) oil, and is the developer and manufacturer of CannaVEST’s own award winning CBD Simple™, and US Hemp Oil, LLC (www.USHempOil.com), which provides seed procurement, cultivation, processing, and production consultation, and equipment to support U.S. farmers, researchers and businesses to cultivate and process industrial hemp in the US.US Hemp Oil plans to build seed-processing mills and bring hemp-based products to market.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of CannaVest Corp. to be materially different from the statements made herein.

(SIMH) Caregiver TouchFree Infrared Clinical Thermometer Awarded

Annual Event Identifies Healthcare Products That Improve Patient Outcomes and Enhance Patient and Provider Safety

MIAMI, Oct. 24, 2014  — Thermomedics, Inc, a division of Sanomedics (OTCQB:SIMH) announced that its Caregiver® TouchFree™ Clinical Thermometer was awarded the coveted Innovative Technology designation by Novation at its Innovative Technology Expo on Sept. 10, 2014, at the Irving Convention Center, Irving, Texas.

The Caregiver does not require probe-covers, since it does not contact the patient, making it ideal for reducing risk of transmission of infectious disease. It takes temperature in 1-2 seconds and is easy-to-use with minimal inservice. The lack of probe covers also contributes to reduction of plastic waste and reduces costs for storage, as well.

The Caregiver was awarded the Innovative Technology designation following a review by more than 200 attendees from hospitals around the United States who serve on a Novation council or task force and participated in the Expo. These key opinion leaders indicated the Thermomedics Caregiver device offered incremental benefit over other products available on the market.

Olya Carter, RN and Senior Clinical Manager at Novation said, “Hospital participants strongly supported the Thermomedics Caregiver TouchFree Thermometer. They identified the Caregiver as the way to provide superior patient care by allowing them to efficiently assess their patients in the safest possible way.”

Keith Houlihan, Company President, noted that “this medical instrument is a breakthrough in patient care and reduces costs, time and technique-dependence while upgrading standards of practice. Our TouchFree technology is the world leader in contagion risk avoidance.”

This new designation will also identify Thermomedics’ Caregiver® TouchFree™ Clinical Thermometer as an awarded Innovative Technology product within Novation’s online contract catalog, which is accessible by the more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association, and Provista served by Novation. This heightened visibility will encourage further consideration by members accessing this agreement.

To learn more about Novation’s Innovative Technology program, visit www.novationco.com/expertise/technology.

About Sanomedics International Holdings, Inc.

Sanomedics International Holdings, Inc. (OTCQB:SIMH) is a medical technology holding company that focuses on game changing products, services and ideas — a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services.

Sign up for Sanomedics email news alert system today at: http://ir.stockpr.com/sanomedics/email-alerts.

Follow us on Twitter @Sanomedics and tweet us!

About Novation, Winner of the Ethics Inside® Certification

Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 100,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children’s Hospital Association, an alliance of the nation’s leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 800 suppliers. Members of VHA, UHC, Children’s Hospital Association and Provista used Novation contracts to purchase approximately $49 billion in 2013. Novation has earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere’s World’s Most Ethical Companies list and is the only company in the health care industry to earn both distinctions for three consecutive years. To learn more about Novation, please visit http://www.novationco.com and follow @NovationNews.

Forward Looking Statements

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition is not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company’s periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.

CONTACT: Keith Houlihan
         Sanomedics International Holdings, Inc.
         info@Sanomedics.com

(VIZC) In-Depth Feature TV Interview On “New To The Street”

(INNV) Receives Approval for the Expanded Label Indication for Zestra in Canada

SAN DIEGO, CA /  October 24, 2014 / Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTC: BB: INNV) today announced that it has received approval from Health Canada for an expanded label for its marketed Zestra(R) product. Zestra(R) is currently approved and marketed in Canada for the indication of “Temporary Increase of Desire in Female Sexual Desire Disorder Women (“FSDD”)”. The new indication approved is expanded to that of “Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal Disorder” (“FSI/AD”).

FSI/AD, is a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. FSI/AD is a larger market that that of FSDD and published papers on the FSI/AD market size such as Harris, Interactive Women’s Sexual Health Survey (2009) estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger with an estimated over 20 million women suffering in the US and over 2 million women suffering in Canada.

There are no current prescription products approved in Canada or anywhere in the world for this indication which makes Zestra(R) a very valuable product to treat such an indication where it is approved.

Zestra(R) is the only OTC natural product clinically proven in two U.S. double-blind, placebo controlled trials in 276 women to increase arousal, desire and reduce pain during sexual intercourse. Zestra(R) is currently commercialized in the U.S. by the Company and in Canada by the Company’s licensing partner, Orimed Pharma Inc., a subsidiary of Jamp Pharma, and has sold millions of units since its launch in 2007. According to Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542 and deKadt Zestra Quantitative Consumer Study, October 2009, 43% of women have sexual difficulties as compared to ~31% of men who have erectile dysfunction (a market size close to $6B worldwide).

“The expanded label makes Zestra(R) the only product approved and marketed in Canada for FSI/AD and makes the product the first-to-market for this large therapeutic indication in this country”, said Dr. Damaj, President & Chief Executive Officer of the Company. “Our efforts to commercialize this product in additional markets such as Europe are moving forward as the Company is preparing for scientific guidance from the European Medicine Agency for filing Zestra(R) as a Herbal-based Medicine in Europe for the same indication,” continued Dr. Damaj.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in the OTC male and female sexual dysfunction products. The Company generates revenues from its lead products Zestra(R) for female arousal, and EjectDelay(TM) for premature ejaculation, and has a total of four marketed products in this space including Sensum+ (formerlyCIRCUMSerum(TM) (for sales outside the U.S. only) and Zestra(R) Glide.

For more information, go to www.innovuspharma.com.

INNOVUS PHARMA’S FORWARD-LOOKING Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R) in Canada, to successfully commercialize such products, and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

Innovus Pharma Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

(LTNC) Elects New Board Member

HIRAM, GA /  October 24, 2014 / Labor SMART, Inc. (LTNC) (the “Company”), a leader in providing on-demand blue collar staffing primarily in the southeastern United States, today announced that James Robert “Bobby” Edmonds of California, has been elected to the company’s board of directors. This brings the current total of directors to three.

Mr. Edmonds brings 17 years of experience in IT infrastructure and operations, including 14 years of software and application development expertise. He has held positions in networking, telecommunications, cloud and mobility solutions, both for B2B and B2C. In recent years his efforts have focused on tactical, strategic and marketing aspects of enterprise product development in his position of principal product manager at ServiceNow, a cloud services company.

“Bobby provides Labor SMART with a unique perspective and additional expertise to our board,” said Ryan Schadel, CEO of Labor SMART. “He is recognized as one of Silicon Valley’s experts in platform development and we believe that as we grow our business, seek new ways to engage with customers, and work to consolidate systems to bring about better EBITDA margins, his expertise will be of great value.”

“It is a great opportunity and an exciting time to join the board of directors of Labor SMART,” said Mr. Edmonds. “I look forward to supporting Mr. Schadel and his team as they continue to grow Labor SMART into the market disruption it was designed to become. The future of Labor SMART is a bright one and I am honored to be a part of it.”

Mr. Edmonds is 37 and is a U.S. Air Force veteran. He resides in Silicon Valley, California.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Labor SMART, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may”, “would”, “will”, “expect”, “estimate”, “can”, “believe”, “potential”, and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Labor SMART, Inc.’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Labor SMART, Inc.’s filings with the U.S. Securities and Exchange Commission.

Contact:

Beverly Jedynak
Martin E. Janis & Company, Inc.
312-943-1123
bjedynak@janispr.com

(GTATQ) Announces Settlement Agreement With Apple

GT Retains Ownership of Production Assets in Mesa and Ability to Sell ASF(R) Furnaces in the Marketplace Without Restrictions

MERRIMACK, N.H., Oct. 23, 2014  — GT Advanced Technologies Inc. (OTC Pink:GTATQ) and Apple have reached a settlement agreement under which GT will wind down its sapphire materials production in the company’s Mesa, AZ and Salem, MA locations. The company indicated that it will exit from the market as a producer of sapphire materials and will refocus its business as an equipment supplier, manufacturing and developing sapphire growth systems and processes.

Under the terms of the settlement agreement, which is subject to approval by the Bankruptcy Court, GT will be released from all exclusivity obligations under its various agreements with Apple. GT will retain ownership of all production, ancillary and inventory assets located in Mesa and Apple is provided with a mechanism for recovering its $439 million pre-payment made to GT over a period of up to four years without interest, solely from a portion of the proceeds from ASF® sales. The agreement provides for a mutual release of any and all claims by both parties. As a result of the agreed upon terms, GT retains control of its intellectual property and will be able to sell its sapphire growth and fabrication technology, including ASF and Hyperion™, without restrictions.

GT and Apple will continue their technical exchange involving the development of processes for growing next generation sapphire boules as GT continues to build on its successfully deployed ASF115Kg technology and expand its range above 165Kg.

“We are pleased with the settlement that we have negotiated with Apple,” said Tom Gutierrez, president and chief executive officer. “We realize that our filing for Chapter 11 protection has caused uncertainty and hardship for many of our important stakeholders. We have been working diligently to develop a restructuring plan that will allow us to emerge from Chapter 11 as quickly as possible and with the operating flexibility and resources to position GT for long-term success. This agreement with Apple is an important step in that direction as it will allow us to monetize our advanced sapphire growth and fabrication technologies in an unrestricted manner. In addition to continuing to sell our industry leading sapphire equipment, we remain committed to advancing our Merlin™, Hyperion™ and next-generation PV and polysilicon solar solutions.”

As a result of the decision to wind down its sapphire materials operations, earlier this week GT initiated the process of shutting down the Mesa facility and approximately 650 Mesa employees have been laid off. A group of Mesa employees will remain on board to help with the wind down of the facility over the coming months. The company expects that there will be additional reductions-in-force implemented in the coming days, which will impact its Salem, MA, Merrimack, NH and select Asia locations.

“We recognize and regret the impact that these actions have on our valued employees and their families and we are committed to supporting them through this transition,” Gutierrez concluded.

A redacted version of the Settlement Agreement is attached to this press release: http://media.globenewswire.com/cache/25489/file/29707.pdf

GT will file its motion seeking bankruptcy court approval of the settlement agreement on Monday October 27, 2014, and the Bankruptcy Court is scheduled to hear such motion on November 25, 2014.

About GT Advanced Technologies Inc.  

GT Advanced Technologies Inc. is a leading diversified technology company producing advanced materials and innovative crystal growth equipment for the global consumer electronics, power electronics, solar and LED industries. Its technical innovations accelerate the use of advanced materials, enabling a new generation of products across this diversified set of global markets. For additional information about GT Advanced Technologies, please visit www.gtat.com.

Forward-Looking Statements

Some of the information in this press release relates to future expectations, plans and prospects for the Company’s business and industry that constitute “forward-looking statements” for the purposes of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.  Forward-looking statements include, but are not limited to the following: the Company will wind down its sapphire materials production in the company’s Mesa, AZ and Salem, MA locations; the Company will exit from the market as a producer of sapphire materials and will refocus its business as an equipment supplier, manufacturing and developing sapphire growth systems and processes; the Company will retain control of its intellectual property and will be able to sell its sapphire growth and fabrication technology, including ASF and Hyperion™, without restrictions; the Company and Apple will continue their technical exchange involving the development of processes for growing next generation sapphire boules as the Company continues to build on its successfully deployed ASF115Kg technology and expand its range above 165Kg; the agreement with Apple will allow the Company to monetize its advanced sapphire growth and fabrication technologies in an unrestricted manner; and the Company expects that there will be additional reductions-in-force implemented in the coming days, which will impact its Salem, MA, Merrimack, NH and select Asia locations. These forward-looking statements are not a guarantee of performance and these statements involve certain risks and uncertainties that may be beyond the Company’s control and may cause actual future results to differ materially from our current expectations both in connection with the settlement agreement with Apple, the Chapter 11 filings and the Company’s business and financial prospects.  Statements of management’s expectations, including its ability to successfully restructure, to address its financial challenges, obtain debtor-in-possession financing, the ability to address important issues in an orderly way and to make the Company stronger and more competitive are based on current assumptions and expectations.  No assurance can be made that these events will come to fruition.  Factors that could affect our results include, but are not limited to: (i) market demand for the Company’s equipment tools (including ASFs), (ii) the ability of the Company and its subsidiaries to continue as a going concern, (iii) the ability of the Company to obtain debtor-in-possession financing in adequate amounts; (iv) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases, (v) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases, and (vi) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents. Other factors that may cause actual events to differ materially from those expressed or implied by the forward-looking statements and various other risks are outlined in GT Advanced Technologies Inc.’s filings with the Securities and Exchange Commission, including the statements under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 28, 2014 and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Statements in this press release should be evaluated in light of these important factors. The statements in this press release represent GT Advanced Technologies Inc.’s expectations and beliefs as of the date of this press release. GT Advanced Technologies Inc. anticipates that subsequent events and developments may cause these expectations and beliefs to change. GT Advanced Technologies Inc. is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Media
         GT Advanced Technologies Inc.
         Jeff Nestel-Patt
         Jeff.Nestelpatt@gtat.com
         603-204-2883

         Investors/Analysts
         GT Advanced Technologies Inc.
         Ryan Flaim
         Ryan.Flaim@gtat.com
         603-681-3689

(RCHA) Submission of IND for AML and Myelodysplastic Syndrome

BEVERLY HILLS, Calif., Oct. 23, 2014  — Rich Pharmaceuticals, Inc. (OTCQB:RCHA) (“Rich” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.

“We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS,” said Ben Chang, Chief Executive Officer. Rich submitted the IND for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS.

About Rich Pharmaceuticals:

Rich Pharmaceuticals, Inc. (OTCQB:RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals’ goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals’ primary development stage product candidate which is known as RP-323 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.

Notice Regarding Forward-Looking Statements:

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

CONTACT: Ben Chang, CEO
         9595 Wilshire Blvd., Suite 900
         Beverly Hills, CA 90212
         424-230-7001 EXT 105

(DAX) Recon Capital Launches the Only ETF to Track Germany’s

ETF Offers Highly Liquid Exposure and Low Cost to Blue-Chip German Stocks

Recon Capital, an investment firm and Exchange Traded Fund (ETF) provider, began trading the Recon Capital DAX Germany ETF (NASDAQ:DAX) on the NASDAQ Global Market today. The ETF provides investors with access to Germany, the Eurozone’s leading economy, with broad and highly liquid access to leading German blue-chip equities at a total annual operating expense ratio of 0.45%.

“Germany continues to be among the most promising and compelling economies in Europe. As the trusted measure of German blue-chips, DAX is one of the leading indices for financial products in the world. For the first time, it underlies ETFs in three key financial centers in Europe, Asia and now the United States,” said Hartmut Graf, chief executive officer, STOXX Limited. STOXX Ltd. is the marketing agent for the indices of Deutsche Börse AG and SIX, including the DAX and SMI indices.

DAX measures the development of the 30 largest and most liquid companies on the German equities market and represents around 80 percent of the market capitalization in Germany. It currently serves as the basis for more than 135,000 financial products and is one of the largest underlyings for derivatives globally.

“Germany is the locomotive of Europe and, with the Recon Capital DAX Germany ETF, we are giving U.S. investors access to the German equity market which proved to be comparably robust in displaying higher returns and lower volatility levels than most of its European counterparts,” said Garrett Paolella, CEO of Recon Capital. “Recon Capital focuses on using its investment expertise and operational infrastructure to deliver market-driven, value-added products that meet the evolving needs of global investors.”

About Recon Capital Partners:

Recon Capital Partners, LLC is an SEC registered investment adviser headquartered in Greenwich, Connecticut. Recon Capital provides better investment solutions for institutional investors, financial professionals, and individual investors in a liquid, transparent, and cost effective manner. Recon deploys its strategies through several formats including its exchange traded fund platform. For more information, visit http://www.reconfunds.com and www.reconcapitalpartners.com.

About Deutsche Börse

Deutsche Börse is one of the world’s leading data and technology service providers for the securities industry with a product and service offering for issuers, investors, intermediaries and data vendors. The Group covers the entire value chain from trading, through clearing, to settlement and securities custody. Deutsche Börse Market Data + Services encompasses the Group’s extensive market data offering and external technology and connectivity services. The product and service range includes real-time and historical data from the Group’s trading venues Eurex and Xetra as well as from cooperation partners. It also includes exclusive trading signals independent of its platforms such as economic indicators or macroeconomic news, reference data for more than 1,000,000 securities, approximately 10,500 indices including the STOXX and DAX index families, superior capital market infrastructure, and reliable connectivity services.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

Risk considerations

Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. A prospectus with this and other information about the Fund is available at www.ReconFunds.com or by calling 203-900-1400. The prospectus should be read carefully before investing.

The Recon Capital DAX Germany ETF (the “Fund”) is registered with the U.S. Securities and Exchange Commission as a non-diversified, management investment company, pursuant to the Investment Company Act of 1940. An investment in the Fund is subject to risk, including the loss of principal amount invested. There is no guarantee the Fund will achieve its investment objective. The Fund’s shares may be more volatile than the performance of a broadly diversified portfolio. The Fund is not by itself a complete or balanced investment program.

Shares of ETFs are bought and sold at market price (not net asset value (NAV)) and can be acquired or redeemed directly from a fund at NAV in Creation Units only. Brokerage commissions will reduce returns. Market returns are based upon the midpoint of the bid/ask spread at 4:00 p.m. eastern time (when NAV is normally determined for most ETFs) and do not represent the returns you would receive if you traded shares at other times.

Market forces may result in shares trading at a significant premium or discount to NAV. Although the shares are currently listed on an exchange, there can be no assurance that an active trading market for the shares will develop or be maintained.

The Fund’s performance is expected to be closely tied to social, political, and economic conditions within Europe and to be more volatile than the performance of more geographically diversified funds. An investment in European securities can be adversely affected by a variety of factors, among which are: restrictions on inflation rates, deficits, interest rates, debt levels and fiscal and monetary controls imposed by the European Union or European Monetary Union; historically high unemployment and significant debt problems in certain European nations; recently volatility in European financial markets due to concerns about economic downturns or rising government debt levels. Currently, a significant portion of the Index is allocated to securities of companies in France, Germany and Spain.

Recent events have adversely affected the exchange rate of the euro and may continue to significantly affect every country in Europe, including countries that do not use the euro. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the Fund’s investment and the value of your Fund Shares. Because the Fund’s NAV is determined in U.S. dollars, the Funds NAV could decline if the currency of the non-U.S. market in which the Fund invests depreciates against the U.S. dollar, even if the value of the Fund’s holdings, measured in the foreign currency, increases.

The DAX Index and its related trademarks are proprietary to STOXX Limited. The DAX Index and the related trademarks have been licensed for certain purposes by Recon Capital. The Recon Capital DAX Germany ETF is not sponsored, sold, endorsed or promoted by STOXX Limited.

# # #

Recon Capital and Recon Capital Partners are registered with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries. All other trademarks or registered trademarks are the property of their respective owners.

(BFRE) Receives Unprecedented Export-Import Bank of China Letter of Intent

BlueFire’s Mississippi Fulton Project Paves the Way for Other U.S./China Renewable Energy Projects

IRVINE, Calif., Oct. 23, 2014  — BlueFire Renewables, Inc. (OTC:BFRE), a company focused on changing the world’s transportation fuel paradigm through the production of renewable fuels, announced that it has received a Letter of Intent from The Export Import Bank of China (China EXIM) to provide up to $270 million in debt financing for its bio-energy project in Fulton, Mississippi.

China EXIM’s interest in providing substantial financing to BlueFire is unprecedented and significant for the U.S. renewable energy sector and for U.S. renewable energy small businesses. Particularly in the capital-intensive energy industry, small businesses like BlueFire struggle to access capital amidst tightening credit markets in the U.S. since the financial crisis beginning in 2009.

“This is a significant feat, not just for BlueFire as it also provides a model for the U.S. small business community because it is a strong indication of China’s commitment to support and fund U.S. renewable energy technologies to improve the environment and build a strong foundation for cooperation between China and the U.S. in the field of renewable energy,” stated Arnold Klann, CEO of BlueFire Renewables, Inc.

“There are significant opportunities for replicating the BlueFire Fulton size or larger facilities in China and the U.S. to deal with problematic agricultural and urban waste currently being burned or buried,” Klann said. “Debt financing has been the most difficult part of the financing to obtain for the cellulosic biofuels industry. BlueFire’s business model and relationships with China EXIM will set the standard for future debt financing arrangements and could be the spark that leads to the more beneficial use of cellulosic wastes in the bio-fuels industry in the U.S. and China. We are cracking the code when it comes to striking a win-win business deal for China, the U.S. and energy consumers.”

Klann said that BlueFire has been working with China EXIM in response to the China Strategic and Economic Dialogue with the U.S., which encourages U.S./China cooperation in the renewable energy field. Due to the difficulty in obtaining financing for capital-intensive energy projects, many renewable energy projects do not get past the pilot phase and into the full commercial development stage. Dozens of renewable energy projects in the U.S. are languishing because of the debt-financing problem and the BlueFire solution could be the path to commercialization for many of these projects.

Because Loan Guarantee programs offered by U.S. Federal agencies (the Department of Energy and the Department of Agriculture) were not structured for small businesses, the BlueFire/China EXIM framework with major Chinese companies will open the door for more businesses in the U.S. to finance and build projects, not only in the U.S., but in China.

The Letter of Intent continues the international collaboration between U.S. and China initiated by BlueFire. “Combining the already announced engineering and project management contract with China Three Gorges, which is China’s largest utility, and now the addition of funding intended by the China EXIM Bank, both countries can work on the sustainable production of renewable fuels and chemicals while promoting jobs and the use of domestic and readily available biomass resources,” said Klann.

The companies will continue to work together to complete the standard due diligence procedures of the China EXIM bank and meet all credit criteria and condition precedent to reach definitive agreements in order to complete the financing as soon as possible. Once completed, China Three Gorges Corporation and its U.S. subcontractors will begin construction of the Fulton Project.

The Fulton, MS project will allow BlueFire to utilize green and wood wastes available in the region as feedstock for the ethanol plant that is designed to produce approximately 19-million gallons of ethanol per year.

About BlueFire Renewables, Inc.

BlueFire Renewables, Inc. was established to deploy the Arkenol patented and proven Concentrated Acid Hydrolysis Technology Process for the profitable conversion of cellulosic waste materials (“Green Waste”) to renewable fuel sources. BlueFire has demonstrated production of Biofuels from urban trash (post-sorted MSW), rice and wheat straws, wood waste and other agricultural residues.

BlueFire was awarded a grant totaling $88 million under the American Recovery and Reinvestment Act in December of 2009. BlueFire’s biorefineries will be located near markets with high demand for ethanol and will use locally available biomass. This should dramatically reduce delivery costs and increase biofuel supplies, while providing a unique waste processing technology to help America’s cities better manage the increasing problem of overflowing landfills. For more information, please visit www.BFREINC.com.

About The Export-Import Bank of China

The Export-Import Bank of China is one of three institutional banks in China chartered to implement the state policies in industry, foreign trade, diplomacy, the economy, and provide policy financial support so as to promote the export of Chinese products and services. It was established in 1994 and has a focus to promote foreign trade and investment as well as development assistance through concessional funding and other types of financing. Its main areas of business are energy, infrastructure, telecom, mining, and industrial sectors.

Forward-Looking Statements

Statements about BlueFire Renewables expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. BlueFire’s actual results could differ materially from expected results.

This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). BlueFire Renewables, Inc. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” or “anticipates,” and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful development and deployment of ethanol production facility or facilities, impact of the company’s expansion plan, new business development success, future financial results, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks and other factors are detailed in the Company’s regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company’s control. Forward-looking statements speak only as to the date they are made and BlueFire Renewables, Inc. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

CONTACT: Company Contact:
         Richard Klann
         BlueFire Renewables, Inc.
         rgklann@bfreinc.com
         949.588.3767, ext. 411

(NEWT) Small Business Economy Continues To Grow Modestly

Newtek, The Small Business Authority®, Releases September 2014 SB Authority Index

NEW YORK, Oct. 23, 2014  — Newtek Business Services, Inc. NASDAQ: NEWT, The Small Business Authority^®, announced today the release of the SB Authority Index of small business indicators for September 2014 which reached 129.17 points. The Russell Microcap Index, new entity formation and retail sales led the increase. The SB Authority Index is up 0.28% from August 2014. On a year-over-year comparison, the SB Authority Index is up 5.88%.

Barry Sloane, Chairman, President and CEO of The Small Business Authority^® commented, “Another tepid increase for the small business economy in the September Index as we are experiencing a roller coaster ride in the coastal markets. The Russell Micro-Cap Index and interest rates are experiencing extreme volatility, coupled with worldwide events such as ISIS and Ebola threatening the small business economy. These events tend to lead to the type of uncertainty that slows the small business economy and creates hesitancy amongst independent business owners.”

About Newtek Business Services, Inc.

Newtek Business Services, Inc., The Small Business Authority^®, is the Authority for the small- and medium-sized business (SMB) market providing a wide range of business services and financial products under the Newtek^® brand. Since 1999, Newtek has provided state-of-the-art, cost-efficient products and services and efficient business strategies to over 100,000 business accounts across all 50 States to help them grow their sales, control their expenses and reduce their risk.

Newtek’s products and services include: The Newtek Advantage^™, Electronic Payment Processing, Managed Technology Solutions (Cloud Computing), eCommerce, Business Lending, Insurance Services, Web Services, Data Backup, Storage and Retrieval, Accounts Receivable Financing, Payroll.

The Small Business Authority^® is a registered trade mark of Newtek Business Services, Inc., and neither are a part of or endorsed by the U.S. Small Business Administration.

Note Regarding Forward Looking Statements

Statements in this press release including statements regarding Newtek’s beliefs, expectations, intentions or strategies for the future, may be “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the plans, intentions and expectations reflected in or suggested by the forward-looking statements. Such risks and uncertainties include, among others, intensified competition, operating problems and their impact on revenues and profit margins, anticipated future business strategies and financial performance, anticipated future number of customers, business prospects, legislative developments and similar matters. Risk factors, cautionary statements and other conditions, which could cause Newtek’s actual results to differ from management’s current expectations, are contained in Newtek’s filings with the Securities and Exchange Commission and available through http://www.sec.gov.

FROM:
Newtek Business Services, Inc.
http://www.thesba.com
Contact: Simrita Singh
Telephone: (212) 356-9566 / ssingh@thesba.com
Investor Relations
Contact: Jayne Cavuoto
Telephone: (212) 273-8179 / jcavuoto@thesba.com
Contact: Brett Maas
Telephone: (646) 536-7331 / brett@haydenir.com

(BVNRY) Licensing/Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine

– Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson licenses MVA-BN-based Ebola/Marburg vaccine from Bavarian Nordic – Bavarian Nordic will scale up and is targeting to manufacture more than 1 million doses of the prophylactic vaccine in 2015 for clinical trials and emergency use in the current Ebola outbreak in West Africa – Johnson & Johnson Development Corporation invests DKK 251 million (approximately US$ 43 million) in new Bavarian Nordic shares – Total potential agreement value including upfront payments, equity investment, milestones and supply contract in excess of US$ 187 million – The company raises its expectations to year-end cash preparedness

KVISTGAARD, Denmark, Oct. 22, 2014  — Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Under the terms of the agreement, Bavarian Nordic will grant Janssen an exclusive license for its multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus. Bavarian Nordic will receive an upfront payment of US$ 25 million and is entitled to up to US$ 20 million in development and regulatory milestones, in addition to royalties for commercial sales outside Africa. Janssen will be fully responsible for all costs associated with the development and commercialization of the vaccine.

In addition, Bavarian Nordic will scale up its production and is targeting to manufacture more than 1 million doses of the vaccine valued at US$ 99.3 million, of which Janssen will make an upfront payment of US$ 70.8 million. The remaining US$ 28.5 million will be received pro rata with deliveries in 2015.

A combination vaccine regimen of Bavarian Nordic’s multivalent MVA-BN Filovirus vaccine and Janssen’s AdVac(R) technology recently demonstrated complete protection against Ebola in preclinical studies and Janssen will now undertake further clinical investigation of this regimen. Furthermore, Janssen is working closely with authorities as part of its prioritized efforts to make the vaccines available for emergency use to help contain the current outbreak in West Africa.

Additionally, through a private placement, Johnson & Johnson Development Corporation will invest DKK 251 million (approximately US$ 43 million) to subscribe for new shares of Bavarian Nordic. Further details on the subscription of shares will be announced separately.

“We are very pleased to partner with Janssen on the development and supply of an Ebola vaccine to help contain the current outbreak which now constitutes a global health concern. As part of our ongoing work with the US Government, we have been developing potential vaccines against Ebola for several years. The gravity of the situation has called for immediate action from authorities and drug developers to fast-track the development of urgently needed medical countermeasures, and we are happy to join this effort together with Janssen who has demonstrated their leadership by committing to accelerating this vaccine and actively supporting the areas in West Africa affected by the outbreak,” said Paul Chaplin, Ph.D. and Chief Executive Officer of Bavarian Nordic.

Improved cash preparedness

As a consequence of the agreement, the Company raises its expectations for the year-end cash preparedness from approximately DKK 600 million to DKK 1,000 million including a reduction in debt and credit facilities of approximately DKK 150 million. The expectations for full year revenues and result are maintained as the vast majority of the agreement will be revenue recognized in 2015.

Conference call and webcast

The management of Bavarian Nordic will host a conference call today at 2 pm CET (8 am EDT) to discuss the agreement. Dial-in numbers for the conference call are: Denmark: +45 32 72 80 18, UK: +44 (0) 844 571 8957, USA: +1 866 682 8490. A live and archived webcast of the call will be available at www.bavarian-nordic.com/investor/webcast.aspx.

About Bavarian Nordic

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC(R), an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE(r), a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX.

Bavarian Nordic’s shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit www.bavarian-nordic.com.

About Ebola

The Ebola virus belongs to a virus family called Filoviridae and can cause severe hemorrhagic fever in humans and nonhuman primates. Ebola has a mortality ranging from 50% to 90% according to the World Health Organization. The virus is highly prioritized by the U.S. Government, who has defined the virus as a “Category A” agent that poses a risk to national security. Currently, there exists no approved treatment or vaccine against the disease.

About MVA-BN(R)

MVA-BN (Modified Vaccinia Ankara – Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and adaptable platform suitable for addressing a wide variety of infectious diseases, including biological threats.

In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU and Canada) essential to protecting the immune-compromised population, Bavarian Nordic has conducted more than a dozen preclinical and clinical studies of recombinant MVA-BN-based vaccines.  More than 7,500 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Rolf Sass Soerensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43

Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

(FCCN) Announces Launch of Market News Analysis Platform for Investors

Monitr provides a significant advantage to investors by uncovering the news and information, in real time, that are influencing markets and the equities that are most impacted positively or negatively at any given time.

Spectral Capital Corporation, (FCCN.QB), announced today that portfolio company Monitr has launched its financial market news analysis platform and service. The Monitr platform finds, aggregates and analyzes thousands of news articles and opinions daily, calculating the sentiment, trend and impact on equities, sectors and indices for each article or social media post in real time. The Monitr service provides analysis for over 7,000 publicly traded companies, major indices like the S&P500, Dow Jones and Russell 2000 and exchanges including the NYSE, Nasdaq and TSX.

Over the past decade, there has been an enormous increase in the production and distribution of financial news and opinion. The amount and flow of new information reporting and commenting on equities and markets has moved well beyond the consumption abilities of even the most advanced financial organization or retail investor. Monitr, leveraging the power of the cloud and its proprietary algorithms, aims to provide these investors and traders with the tools, data and services that will allow them to follow and analyze all the news, from all markets for all equities. Monitr users have a significant advantage by being able to uncover the news and information that are influencing markets and the equities that are most impacted positively or negatively at any given time.

The Monitr service is web-based making it easy to access from any desktop device or tablet. The service provides easy to interpret market visualization tools, competitor comparisons, portfolio management along with fine-grained analysis for equities, industries and sectors for the past 30 days. In addition to tools to follow, monitor and interpret market news, trends and sentiment, Monitr provides daily updates, real time alerts and signals via email and Twitter.

“Monitr is a very ambitious project and now that it is available to the public, it has the potential to be a game-changer for individual investors, as well as financial institutions and hedge funds,” said Jenifer Osterwalder, Spectral CEO. “The use of technology has become integral in making informed investment decisions, and Monitr provides groundbreaking analysis of what, up until now, has been an underutilized market signal – news and opinion.”

Immediate enhancements planned for Monitr include further development of the Monitr Rank algorithm, as well as refinement of the algorithms underlying the analysis of sentiment and the calculation of audience impact for news mentions. Enhancements to existing algorithms will bring even more precision to the analysis available on the Monitr platform.

“We know, based on early feedback, that Monitr is already an essential tool for professionals in financial markets. We are focused on making Monitr a need-to-have tool for every investor who strives to make data-driven investment decisions,” commented Dennis Lutsky, Monitr founder and CEO.

In addition to individual accounts, Monitr is available to larger financial institutions via customizable data feeds and on the web as Software as a Service (SAAS).

For more information and to sign up for Monitr’s free or paid services, visit www.monitr.com

ABOUT SPECTRAL:

Spectral Capital (FCCN) is a publicly traded technology startup accelerator that invests primarily in emerging and fast growth technology markets. We offer shareholders an ideal way to invest in early stage startups with the added benefit of investment liquidity through public exchanges. We acquire companies that are developing technologies and solutions to challenging business problems and needs. Spectral guides and mentors each new venture, keeping them on track and focused on growth. Spectral Capital has offices and operations in North America and Europe.

ABOUT MONITR:

Monitr is a technology and financial data services company. Monitr specializes in the analysis of news, opinion and social media to determine the aggregate sentiment and trends of equities, commodities and currencies across world markets. It offers these services direct to customers on the web as Software as a Service and via customized data feeds for financial institutions and hedge funds.

PRESS RELEASE FORWARD LOOKING STATEMENT:

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth and business strategy. Words such as “expects,” “will,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations on such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Factors that could cause actual results to differ materially include, but are not limited to, changes in the Company’s business; competitive factors in the market(s) in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

(HPTG) Announces Planned Installation of HydroPlant on Public Transportation Buses in Poland

Water-Based Hydrogen Fuel Production Systems Designed to Improve Fuel Efficiency and Reduce Greenhouse Gas Emissions

(RGLS) microRNA Platform Monotherapy Human Proof-of-Concept Shows Promise

LA JOLLA, Calif., Oct. 22, 2014  — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).  Interim results from the ongoing clinical study demonstrate that treatment with a single subcutaneous dose of 2 mg/kg of RG-101 as monotherapy resulted in significant and sustained reductions in HCV RNA in a varied group of patients, including difficult to treat genotypes and patients who experienced viral relapse after a prior IFN-containing regimen.  Additionally, RG-101 was safe and well tolerated and has demonstrated a very favorable pharmacokinetic profile to date, which may allow for combination with oral direct-acting antiviral (“DAA”) agents to treat HCV.

Interim results from the ongoing clinical study are summarized below:

In the first dose cohort of part IV of the ongoing study, 16 HCV patients were enrolled with multiple genotypes, 10 GT1s, 5 GT3s, and 1 GT4. 14 patients, 8 naïve and 6 patients who experienced viral relapse after a prior IFN-containing regimen, received a single subcutaneous dose of 2 mg/kg of RG-101 as monotherapy while 2 patients received placebo.

• In the 14 HCV treated patients, there was a mean viral load reduction of 4.1 log₁₀ at day 29 (range -5.8 log₁₀ to -2.3 log₁₀).
• 6 out of 14 patients had HCV RNA levels below the limit of quantification at day 29 and the 3 patients from this group who have reached day 57 still have HCV RNA levels below the limit of quantification.
• Viral load reduction occurs within the first 96 hours and virologic response is not influenced by IL-28 genotype.
• Due to the long-lasting and sustained virologic effect seen, the ongoing study protocol has been amended to follow patients for up to six months after dosing to evaluate the possibility for certain patients to achieve viral cure after a single dose of RG-101.
• There were no drug-drug interactions from part III of the ongoing study in which RG-101 was combined with simeprevir (OLYSIO™), an approved oral DAA (protease inhibitor), and the combination had no effect on the pharmacokinetic profile of RG-101 or simeprevir (OLYSIO™).
• RG-101 is safe and well tolerated with no serious adverse events reported to date.

“We are very excited to have demonstrated our first human proof-of-concept results with a microRNA therapeutic from the ongoing study of RG-101, which is a significant milestone in Regulus’ history, and represents a key achievement under our ‘Clinical Map Initiative’,” said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus.  “We believe these interim data are exceptional and provide strong evidence to support the rapid advancement of RG-101 into future clinical studies, while presenting a clear opportunity for a potentially disruptive therapy to the current HCV treatment paradigm.”

“RG-101 is the first microRNA therapeutic in clinical development to combine the most advanced RNA technologies from three leading RNA therapeutics companies; chemistry 2.5 from Isis, GalNAc conjugate from Alnylam, and Regulus’ unique and proprietary chemistry including the novel linker that facilitates the release of the parent oligonucleotide after hepatocyte uptake,” said Neil W. Gibson, Ph.D., Chief Scientific Officer. “We believe the innovative design of RG-101 has led to achievement of our first human proof-of-concept results, and hope these findings will advance the growth of our microRNA therapeutics pipeline.”

“We are very pleased and encouraged with the interim results and believe these findings strongly support the rapid advancement of RG-101 into Phase II development,” said Paul Grint, M.D., Regulus’ Chief Medical Officer. “Currently, we plan to file an Investigational New Drug Application with the U.S. Food and Drug Administration in the first quarter of 2015 and plan to initiate a Phase II DAA combination study of RG-101 in HCV patients in the second quarter of 2015.  In addition, we look forward to reporting additional data from the ongoing study in the first half of next year.”

“The efficacy and sustained viral response seen with a single dose of RG-101 is very promising and it was encouraging to see response across a diversity of genotypes and treatment experience in this clinical trial.  Additionally, all patients in the first cohort on active therapy demonstrated a viral response to RG-101, which is also very encouraging,” said Dr. Eric Lawitz, M.D., Vice President, Scientific and Research Development, The Texas Liver Institute, and Clinical Professor of Medicine, University of Texas Health Science Center in San Antonio.  “These findings suggest the clinical benefit of utilizing a unique mechanism of action to potentially treat difficult patient populations.  There may be an opportunity to improve upon the current real world compliance issues with therapies such as RG-101 that may be administered subcutaneously by a clinician.  I look forward to seeing RG-101 advance into future clinical trials.”

Conference Call & Webcast Information

Regulus will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time today to discuss its interim results from the ongoing clinical study of RG-101 for the treatment of HCV.  A live webcast of the call will be available online at www.regulusrx.com.  To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 24374685.  To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode ID 24374685.  The webcast and telephone replay will be archived on the company’s website for ninety days following the call.

About RG-101 for HCV

RG-101 is a wholly-owned, GalNAc-conjugated anti-miR targeting miR-122 for the treatment of HCV.   Regulus is currently evaluating RG-101 in an ongoing study being conducted in the Netherlands.  The study has the following four parts: (I) a single ascending-dose study in which healthy volunteer subjects receive a single subcutaneous dose of RG-101, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg and 8 mg/kg or placebo; (II) a multiple-ascending dose study in which healthy volunteer subjects receive a monthly single subcutaneous dose for four months of RG-101 or placebo; (III) a single-dose drug-drug interaction study in which healthy volunteer subjects receive a single subcutaneous dose of RG-101 in combination with simeprevir, an approved DAA; and (IV) a single-dose study in which HCV patients receive either a single subcutaneous dose of RG-101 or placebo at two doses, 2 mg/kg of RG-101 (the first dose cohort) or 4 mg/kg of RG-101 (the second dose cohort), to assess the safety and viral load reduction.   The primary objective is to evaluate safety and tolerability and the secondary objectives are to evaluate pharmacokinetics, viral load reduction and any impact an oral DAA, such as simeprevir, may have on the pharmacokinetics of RG-101.  Up to 100 healthy volunteer subjects and HCV patients with multiple HCV genotypes and treatment history are planned to be enrolled.

Today, Regulus reported interim results from the above study and plans to report additional results from the ongoing study in 2015.

About microRNAs

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history.  microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 800 microRNAs have been identified in the human genome, and over two-thirds of all human genes are believed to be regulated by microRNAs.  A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome.  microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis, metabolic diseases, immune-inflammatory diseases and HCV. Targeting microRNAs with anti-miRs, chemically modified, single-stranded oligonucleotides, offers a unique approach to treating disease by modulating entire biological pathways and may become a new and major class of drugs with broad therapeutic application.

About Hepatitis C Virus Infection (HCV)

Hepatitis C is a result of a hepatocyte specific infection induced by the virus known as HCV.  Chronic HCV may lead to significant liver disease, including chronic active hepatitis, cirrhosis, and hepatocellular carcinoma. Up to 170 million people are chronically infected with HCV worldwide, and more than 350,000 people die from HCV annually.  The CDC estimates that there are currently approximately 3.2 million persons infected with HCV in the United States.  HCV shows significant genetic variation in worldwide populations due to its frequent rates of mutation and rapid evolution. There are six genotypes of HCV, with several subtypes within each genotype, which vary in prevalence across the different regions of the world. The response to treatment varies from individual to individual underscoring the inadequacy of existing therapies and highlights the need for combination therapies that not only target the virus but endogenous host factors as well, such as microRNA-122.

Regulus believes that its’ miR-122 antagonist, RG-101, may be a useful agent in emerging combination regimens to address difficult-to-treat genotypes and to potentially expand upon the current therapies available to clinicians treating HCV patients.

Update to the ‘Clinical Map Initiative’

Launched in February 2014, Regulus’ ‘Clinical Map Initiative’ outlines certain corporate goals to advance its microRNA therapeutics pipeline over the next several years.  In October 2014, Regulus demonstrated human proof-of-concept with a microRNA therapeutic, RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 for the treatment of HCV.  The company plans to rapidly advance RG-101 in clinical development and expects to initiate a Phase II DAA combination study in HCV patients in the second quarter of 2015.  In addition, Regulus expects to initiate a Phase I clinical study of RG-012 for the treatment of Alport syndrome, nominate a third microRNA candidate for clinical development by the end of 2014, and maintain a strong financial position and end 2014 with at least $75.0 million in cash, cash equivalents and short-term investments.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutics pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Specifically, Regulus is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection.  Regulus’ commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers.  In addition, the Company has established Regulus microMarkers™, a division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected ability of Regulus to undertake certain activities and accomplish certain goals with respect to RG-101, the projected timeline of clinical development activities related to RG-101, and expectations regarding future therapeutic and commercial potential with respect to RG-101. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus’ current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus’ are described in additional detail in Regulus filings with the Securities and Exchange Commission.  All forward-looking statements contained in this presentation speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

OLYSIO™ is a registered trademark of Janssen Therapeutics.

(CSSI) Has Entered Into a Letter Of Intent to Purchase 33% of Incryptex Inc.

CYPRESS, TX , United States, via ETELIGIS INC., 10/22/2014 – – Costas Inc. (OTC Pink: CSSI) (PINKSHEETS: CSSI) is pleased to announce their entering into a formal Letter of Intent to purchase 33% of Toronto-based Incryptex Ltd. www.incryptex.com

Incryptex Ltd. is a digital currency processing platform. Incryptex will allow its global member base to participate in the processing, remittance, and exchange of digital currencies like Bitcoin. The use of proprietary systems exclusive to Incryptex provides Forex, Mining, and Payment Processing Solutions for these products.

Incryptexs proprietary global banking partnerships, risk mitigation strategies, security, and compliance have positioned Incryptex to become a competitive player and service provider in the digital currency space in the US market as well as 132 countries worldwide.

The Costas Inc. will be using their years of experience in trade on ICE, in conjunction with Incryptex proprietary platform. This relationship will provide liquidity, transparency, and security to users worldwide on a user-friendly interface. The technology behind this new platform will open up trade products to users, facilitating their navigation, investment and transactions of crypto currencies globally.

Safe Harbor Statement:

The information you are accessing may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, or similar expressions, or may employ such future or conditional verbs as “may”, “will”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws.

The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company’s various public filings at www.sedar.com and www.sec.gov, including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Ashley Sansalone

President

admin@costasinc.com

(OSLH) Announces the Acquisition of Go Green Hydroponics

YARDLEY, Pa., Oct. 22, 2014  — OSL Holdings, Inc. (OTCQB: OSLH) (“OSL” or “the Company”), a socially conscious business model dedicated to consumer advocacy, social activism and the advancement of civil liberties through the power of commerce, announced today the acquisition of Go Green Hydroponics, Inc. (“Go Green Hydroponics”) a privately held hydroponics, indoor gardening and cultivation supply retail operation, located in Los Angeles, California, specializing in the sale of hydroponic cultivation equipment, mineral nutrient solutions and gardening resources and equipment. Go Green Hydroponics achieved revenues of approximately $2.4 million in the first nine months of 2014 and is expected to reach revenues of approximately $3.0 million in fiscal 2014 with expected future annual revenue increases at a rate of 10% to 15% with expected gross profit margins of approximately 25% to 30%.

OSL acquired Go Green Hydroponics for $1.8 million subject to certain post closing adjustments based on a target working capital amount. OSL also closed on a debt financing transaction in the amount of $1.9 million, the proceeds of which were used to fund the Go Green Hydroponics acquisition and for OSL working capital.

Bob Rothenberg, OSL’s Chief Executive Officer said, “We are very excited about the acquisition of Go Green Hydroponics. Go Green is one of the most highly regarded brands in the vertical, continues to be a profitable business enjoying tremendous growth in the Los Angeles market.”  Steve Gormley, OSL’s Chief Business Development Officer said,  “This acquisition advances OSL’s mission and commitment to our Medical Services Division. OSL continues to support civil liberties through the power of commerce.”

OSL Medical Services is a management, future planning and services platform centered on the development and financing of indoor gardens and cultivation facilities, production technologies, merchandise and operational services for businesses in the herbal and natural medicine industry.  OSL Medical Services is designed to support its clients with branding, technology, marketing, logistics, and future planning services on a state-by-state basis throughout the United States.

OSL Medical Services provides these support services in compliance with all federal, state and local laws. At this time, OSL will not grow or sell marijuana, but intends to gain market share and create value for its shareholders by creating, marketing, and licensing brands as well as acquiring and licensing production technology. When federal law permits, OSL Medical Services expects to provide these services to legal and licensed growers and dispensers.

The hydroponic food production industry is expanding at a rate that is set to outpace the 2014 IMF estimate of global growth by 80%. Hydroponics systems are being deployed to grow key vegetable and fruit crops at scale, driving the transition to safe and sustainable food production worldwide. Agriculture is traditionally a conservative market sector, but the benefits of higher yields with lower inputs, improved soil and water quality, and food safety are compelling forces for change.

The worldwide market value of hydroponically produced food is expected to show sustained strength with a 6.5% compound annual growth rate (CAGR) over the five-year forecast period 2013-2018, beating the IMF estimated growth forecast of 3.6% for 2014. Producer value will increase from $17.7 billion to $24.3 billion. Growth is expected to be steady thanks to the buffering effect of mature European markets, with expected acceleration over the period due to emerging growth in North America and Eastern Europe.

It is estimated that legal medical marijuana cultivators spend $400 million a year on hydroponic gardening, nutrient, equipment and resources supplies in the United States alone.

http://www.gogreenhydrostore.com

About OSL

OSL Holdings, Inc. (OTC: OSLH) is a development and technology company specializing in affluent, liberal markets with high disposal income.  The Company intends to operate a real-time loyalty rewards platform that can facilitate the earning and redemption of rewards currency at the point of the transaction (online, mobile, at retail) as well as on future transactions.  OSL Holdings’ target consumers are highly educated, respond to cause marketing initiatives and socially conscious business models, and are technologically savvy.  On March 10, 2014, the Company announced its intent to enter the legal marijuana market when federal law permits, providing foundational work for branding, marketing, technology, and logistics to existing or emerging legal marijuana licensees.

The Company’s filings with the SEC are available at http://www.sec.gov/cgi-bin/browse-edgar?company=osl+holdings&owner=exclude&action=getcompany.

For more information, please visit the Company’s website at http://www.oslholdings.com.

Forward Looking Statements — Safe Harbor

This press release contains forward-looking statements as defined in the United States Private Securities Litigation Reform Act of 1995.  In some cases you can identify those so-called “forward looking statements” by words such as “may,” “will,” “should,” “expects,” plans,” “targets,” “believes,” “anticipates,” “estimates,” “predicts,” “potential,” or “continue” or the negative of those words and other comparable words.  These statements include, but are not limited to, our expectations concerning Go Green’s revenue growth, growth rates for hydroponically produced food, the market for medical marijuana cultivators, and our ability to provide support services to marijuana growers.

By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.  There are a number of factors, risks and uncertainties that could cause actual results and developments to differ materially from forecasted results.  For a discussion of these factors, risks and uncertainties please see our filings with the Securities and Exchange Commission.  Our public filings with the Commission are available from commercial document retrieval services and at the website maintained by the Securities and Exchange Commission at http://www.sec.gov.  We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.

Company Contact:

OSL Holdings Inc.
IR/Media Contact:
Craig S. Fischer
Communications Manager
O) +1-786-375-0556

Strategic Tactical Asset Trading LLC
1926 Hollywood Blvd
Suite 209
Hollywood,  FL 33020
info@OSLHoldings.com
http://www.OSLHoldings.com
Website: http://www.oslholdings.com

(PLPL) Technology Could Prove Potent in Battling Alzheimers Disease

(IMMB) Enters into Agreement to Market Potential Ebola Virus Treatment

Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company’s ITV-1 Infectious Diseases Treatment in Africa

Company Begins Research of Potential EVD Application of the Patented Proteins

Monrovia, California (FSCwire) – Immunotech Laboratories, Inc. (OTC PINK: IMMB) (“Immunotech” or the “Company”) and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company’s HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa

With the establishment of an African operation, Immunotech hopes to fulfill the Company’s vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus.  In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company’s new agreement with Uldic.

ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus.  IPF is a platform technology that can be used to facilitate a broad range of applications.  It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today.  IPF has not shown itself to be subject to viral resistance, and it is cost effective.

The Company says that the immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens.  CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.

Immunotech has isolated IPF which is the most extensively studied CD 56 ligand to date.  The compounds has their ability to stimulate human NKT-cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor.  A lead compound, IPF, emerged from these studies and this protein exhibits a stronger adjuvant effect in various HIV vaccine platforms in mice.  IPF also provides a protective adjuvant effect with a candidate HIV and HCV vaccine.

While the majority of the Company’s studies have focused on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic to treat infectious diseases.

About Immunotech Laboratories, Inc.

Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immuno-therapeutic treatment and the prevention of HIV/AIDS, Cancer and other immuno-related disorders.

For more information visit: http://www.immunotechlab.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Contact:

Billy Ray: 770-910-5380

Immunotech Laboratories, Inc.

Phone: 818-409-8988

Email:  ir@immunotechlab.com

(RJDG) Moves Forward on Its First Waste Oil Recovery Plant

(NRTI) Scientific/Medical Advisory Board to Meet As CBD Line In Final Phase

Board to Offer Final Review of Product Formulation Prior to Manufacturing and Launch in Medical Marijuana Dispensaries

NEWARK, N.J., Oct. 21, 2014  — Inergetics, Inc. (OTCBB: NRTI), a world-class developer of nutritional supplements, today announced that it will convene a meeting of its Scientific/Medical Advisory Board on November 20, 2014 in San Francisco/Oakland, California. The advisory board is responsible for guiding the formulation of the proprietary line of natural Cannabidiol (CBD)-based nutritional supplements that Inergetics is planning to bring to market next year.

The meeting is being convened by Inergetics’ Chief Science Officer, Carl Germano, RD, CNS, CDN, and will feature the five members of the advisory board: Dr. Justin Fischedick, Dr. Joseph McSherry, Dr. Michelle Sexton, Dr. Yu Shao and Dr. Mark Wallace.  Additional participants will include Inergetics CEO Mike James and CMO Jim Kras.

“As we enter the third and final phase of product development for our CBD line of nutritional supplements, we wanted to convene our Scientific/Medical Advisory Board for its final review of and recommendation on the product formulation prior to our beginning the manufacturing process,” said Carl Germano.  “I look forward to a productive meeting as we continue to mark significant progress toward the market launch of our initial phytocannabinoid product in 2015.”

During the meeting in California, the Inergetics team will be touring dispensaries and an extraction facility, as well as reviewing the branding, packaging and marketing of the product line. Inergetics previously announced that the initial product in the line will incorporate an important cannabinoid from a novel non-cannabis source.  The company expects that the inaugural product’s unique combination of cannabinoids will enable it to deliver additional synergistic benefits in terms of overall efficacy and absorption.

“We are very excited to be entering the final stages of product development for our CBD line of nutritional supplements, beginning with our ‘first to market’ combination cannabinoid product,” said Mike James, CEO of Inergetics. “We are confident that our proven expertise in creating, branding and marketing supplements will translate perfectly to our innovative CBD line of products, and that these products will appeal to consumers experiencing various pain-related ailments,” James added.

Inergetics will be launching its new CBD product line in medical marijuana dispensaries in 2015.

Continued updates on the CBD product initiative and the Scientific/Medical Advisory Board will be made available at http://www.inergetics.com/cbd-initiative/.

Inergetics Media Contact
KARV Communications
Jonathan Leibowitz
(212) 333-0273
Inergetics@KARVCommunications.com

Terra Tech Media Contact
Terra Tech Corp.
Bill Clayton
(888) 603-2896

About Inergetics, Inc.
Inergetics’ portfolio of brands includes: Martha Stewart™ Essentials, a complete line of whole-food-based supplements created specifically for women; Surgex^® Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready^®, a leader in weight loss lifestyle solutions; SlimTrim, the affordable, premium value diet brand; and OmEssentials^®, a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals.

To learn more about Inergetics, visit www.inergetics.com, and the Inergetics brands’ websites at: www.marthastewartessentials.com, www.surgexsports.com, www.surgexsportsblitz.com, www.slimtrim1.com, www.slimtrim.net, www.bikinireadylifestyle.com, www.kahunasands.com, www.omessentials.com.

About Terra Tech Corp.
Terra Tech Corp. (OTCBB: TRTC) through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. Our complete product line is available at specialty retailers throughout the United States, and via our website. Through its wholly-owned subsidiary Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as Shoprite, Food Emporium and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, and Pennsylvania.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of Inergetics set forth herein and those preceded by or that include the words “believes,” “expects,” “given,” “targets,” “intends,” “anticipates,” “plans,” “projects,” “forecasts,” or similar expressions, are “forward-looking statements.” Although Inergetics’ management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause Inergetics’ future results to differ materially from those anticipated. Inergetics assumes no obligation to update any of the information contained or referenced in this press release.

(RSCF) Continues to Solidify Patent Position in Cryogenic Technologies

(NETE) Releases Open Letter to Shareholders

Open Letter to Shareholders Summarizes Recent Milestones

MIAMI, Oct. 21, 2014  — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, releases the following letter to Shareholders from the Company’s Chief Executive Officer, Oleg Firer:

Dear Net Element Shareholders,

I am writing you today for several reasons. The past several weeks have been very busy and productive, and I would like to highlight several achievements that have advanced the Company’s short-term and long-term position both financially and operationally.

Let me begin by first thanking all shareholders for their support. Making an investment is not a light decision and we value the trust you have put into Net Element’s operations, management and service offerings. We continually strive to increase both company and shareholder value, and we believe that you will find evidence of this mission in the achievements we made last month.

Significant Achievements

We kicked off a series of milestones in the month of September by announcing that we will integrate the Apple® Pay service offering into our point-of-sale payment acceptance hardware and software via Apple iPhone 6, iPhone 6 Plus and Apple Watch devices. Aligning Net Element’s services with one of the most reputable companies in the world is an achievement from which we expect to have long-term benefit.

In mid-September we finalized our debt exchange transaction with Crede Capital Group, LLC, eliminating $15,876,860 of debt from the Company’s balance sheet. This transaction, which will be reflected in our financial results for the quarter ended September 30, 2014, significantly freed up our cash flow position and strengthened our balance sheet by replacing debt with equity.

Towards the end of September Net Element secured a new $11 million credit facility from Russia’s largest private bank, Alfa-Bank. The financing supports our growth initiatives in Russia and the Commonwealth of Independent States and is specifically allocated to our TOT Money business, which in April 2014 launched a new cutting-edge platform for mobile commerce, direct carrier billing and payment processing. The credit facility not only strengthened our liquidity, but also facilitates TOT Money’s ability to attract new customers and take advantage of additional growth opportunities in the region.

We also filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). If and when the SEC declares the registration statement effective, we will be able to raise up to $50 million, which we intend to use to execute our business strategy and invest in opportunities in mobile payments and value-added transactional services.

Also notable, brand exposure among the investment community is on the rise. In addition to SeeThruEquity, industry media outlets such as USA Today, TheStreet and 24/7 Wall St. also took notice of our progress and subsequent favorable trading activity following our news releases.

Collectively, these achievements allowed the Company to continue its momentum from our strong second-quarter performance. In the second quarter we received an additional $10 million financing from RBL Capital, after which Cayman Invest converted its $11.2 million of debt to equity. We also expanded our board of directors with the addition of Drew Freeman and William Healy, as well as launched an analytical toolbox product offering to our merchants.

The three months ended June 30, 2014, also marked Net Element’s first quarter of profitability as we reported net income of $1.3 million, or $0.04 per share, compared with a net loss of ($20.2 million), or $(0.72) per share, in the comparative second quarter. Due to restructuring of operations in Russia, second-quarter revenues decreased 12% to $4.9 million from $5.6 million in the second quarter of 2013. Liabilities decreased 40% to $22.8 million from $37.9 million at December 31, 2013. Working capital increased $8.3 million from ($8.0) million at December 31, 2013, to $0.3 million at June 30, 2014, primarily resulting from restructuring our indebtedness.

Outlook

Moving forward, Net Element aims to execute on its initiatives for accelerated growth with sustained profitability. Net Element management and board of directors are committed to reinforcing the company’s underlying business as well as identifying and pursuing strategic opportunities to increase shareholder value.

For the rest of 2014 and moving into 2015 we intend to explore opportunities and the application of our technologies that will continue to propel Net Element toward its potential in the exciting global mobile payments market.

My expectation is that 2014 will unlock additional opportunities that will undoubtedly serve to benefit all who are connected to the success of our Company. On behalf of the entire Net Element family, thank you for sharing in our success and being a partner in our future.

Warm Regards,

Oleg Firer, Chief Executive Officer
Net Element, Inc.
ofirer@netelement.com

About Net Element (NASDAQ: NETE)
Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a next generation cloud-based point of sale payments platform; and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Beeline, Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. More information is available at www.netelement.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow, whether aligning the Company’s services with the Apple suite of products will result in benefits to Net Element and whether any additional financing can be secured by Net Element and whether such additional financing will be adequate to meet the Company’s objectives.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element ‘s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element ‘s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element ‘s ability to successfully expand in existing markets and enter new markets; (iv) Net Element ‘s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element ‘s business; (viii) changes in government licensing and regulation that may adversely affect Net Element ‘s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element ‘s business; (x) Net Element ‘s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

(ESI) SL Rasch Uses Virtual Performance Solution For Architectural Excellence In Medina and Mecca

PARIS, Oct. 20, 2014  — ESI Group , pioneer and world-leading solution provider in Virtual Prototyping for manufacturing industries, announces the recent success of our client, SL Rasch: an architecture firm based in Germany that specializes in innovative buildings and lightweight structures. SL Rasch recently completed two complex architectural projects at the sacred sites of Medina and Mecca. The first was the design of foldable umbrellas that now protect pilgrims from the sun in the Medina Haram Piazza and the second was the design of the Mecca Royal Hotel Clock. Using ESI’s flagship software, Virtual Performance Solution, SL Rasch confidently investigated innovative designs and replaced physical models by virtual tests.

Today, the millions of pilgrims that travel every year to the Great Mosque of Medina, in Saudi Arabia, are sheltered by more than 250 hydraulically powered, foldable umbrellas, each measuring 26 x 26 meters. These translucent umbrellas are folded at night and open up during the day to create a micro-climate beneath them that is up to 8°C cooler than the surrounding area. Pilgrims visiting the important holy site in Mecca can admire the Mecca Royal Hotel Clock, situated at the top of a 601m high tower, which became the second tallest building in the world in 2012.

In order to test their designs of umbrellas for Medina SL Rasch initially used reduced scale physical models, but found that approach to be limiting. Dr. Mahmoud Bodo Rasch, CEO of SL Rasch therefore approached Dr Eberhard Haug, co-founder of ESI Group and author of the Lightweight Structure Analysis code “LISA”, seeking to collaborate in applying simulation methods in the evolution of more elaborate designs for these complex structures.

SL Rasch then virtually built and tested different types of structures using Virtual Performance Solution, ESI’s software that enables the assessment of all domains of product performance around a single core model. This required great care because of the complex geometry and importance of the architectural appearance of the umbrella’s double curve structure. In particular, a form finding process was used to determine a shape that would result in optimal minimum energy – necessary to guarantee that the membranes would last in time and under extreme weather conditions.

For structural analysis of turbulent wind loads on such lightweight structures, the team used Fluid-Structure Interaction (FSI) simulations, coupling Computational Fluid Dynamics (CFD) with Computational Structural Dynamics (CSD); both available as part of Virtual Performance Solution. SL Rasch and ESI co-created special tailor-made modules for modelling naturally turbulent wind loads and optimizing the shape and structure of the umbrellas. These were then used in computer simulations that investigated the safe folding and stowing of the giant umbrellas, taking into account gravity, overlaps, and wind loads. ESI’s unique expertise in the simulation of airbag folding for the automotive industry proved to be highly relevant throughout the studies.

“With the know-how of ESI experts and the capabilities built into ESI’s advanced CAE software solutions, designing our innovative structural systems became possible,” comments Dr Rasch, Founder and Owner of SL Rasch GmbH.

Above: The umbrellas now in place at the Piazza of the Prophet’s Holy Mosque in Medina. ©SL Rasch

Virtual Performance Solution also helped SL Rasch to overcome significant engineering challenges when designing the Mecca Royal Hotel Clock; constructed as a high strength steel structural skeleton clad with lightweight ornamented carbon-epoxy sandwich panels. The giant hollow-section composite clock hands – 23 meters long in the case of the minute clock hand – presented a special challenge as SL Rasch had to ensure these were aerodynamically stable even under high wind velocities and pressure; especially in the least favorable 12 o’clock position, where the danger of periodic aero-elastic flutter was highest. The team performed wind tunnel test and CFD calculations before FSI simulation allowed them to validate their designs.

Above (from left to right): (1) Mecca clock; 2D surface mesh of the clock hands, (2) clock hands flow velocity contours, (3) clock hand velocities, studied using Fluid-Structure Interaction method. ©SL Rasch

By using simulation, instead of building and testing physical prototypes for these two complex projects, SL Rasch was able to test many versions of the design and achieve optimal results while, at the same time, addressing all applicable safety requirements. This study also spared SL Rasch the production of physical prototypes, thereby saving time, considerable costs and environmental waste.

For more information about Virtual Performance Solution, please visit http://www.esi-group.com/virtual-performance-solution

For more pictures of these amazing projects, please visit the page dedicated to the folding umbrellas and the one about the Mecca Clock Tower on SL Rasch’s website

About SL Rasch

SL Rasch specializes in Special Buildings and Lightweight Structures; integrating architecture and engineering. An interdisciplinary team of professionals, composed of architects, structural, mechanical and aeronautical engineers, physicists and computer specialists together with in-house departments for project management, graphic design and model making, brings state of the art techniques and knowledge to design development and problem solving. For more information please visit www.sl-rasch.com.

About ESI Group

ESI is a pioneer and world-leading provider in Virtual Prototyping that takes into account the physics of materials. ESI boasts a unique know-how in Virtual Product Engineering, based on an integrated suite of coherent, industry-oriented applications. Addressing manufacturing industries, Virtual Product Engineering aims to replace physical prototypes by realistically simulating a product’s behavior during testing, to fine-tune fabrication and assembly processes in accordance with desired product performance, and to evaluate the impact on product use under normal or accidental conditions. ESI‘s solutions fit into a single collaborative and open environment for End-to-End Virtual Prototyping. These solutions are delivered using the latest technologies, including immersive Virtual Reality, to bring products to life in 3D; helping customers make the right decisions throughout product development. The company employs about 1000 high-level specialists worldwide covering more than 40 countries. ESI Group is listed in compartment C of NYSE Euronext Paris.

Connect with ESI on LinkedIn, Twitter, Facebook, and YouTube

ESI Group – Media Relations
Céline Gallerne
Celine.Gallerne@esi-group.com
+33 (0)1 41 73 58 46

(NTCXF) Makes First Laser-Processed All-Low-Temperature Solar Cell

Newest innovation to marry black silicon and laser technologies.

RED BANK, N.J., Oct. 20, 2014  — Incorporating its proprietary advances in laser-processing technology, scientists at Natcore Technology (TSX-V: NXT; NTCXF.PK) have created an all-low-temperature, laser-processed solar cell. Their latest device does not require temperatures above 350 degrees C for any process step.

This development sets the stage for a marriage between Natcore’s highly specialized laser processing and its black silicon technology. The fruits of that all-low-temperature marriage would include gains in efficiency and significantly lower production costs.

The milestone was accomplished at Natcore’s R&D Center in Rochester, NY. This is one of the first demonstrations of a low-temperature, laser-processed solar cell by anyone. Further, unlike previous attempts, Natcore’s approach makes it uniquely suited to large-scale manufacturing, especially of high-performance all-back contact cells.

Current silicon processing techniques involve temperatures of 850 degrees C (1,562 degrees F) or higher. But Natcore’s process does not entail temperatures above 350 degrees C for any step. 350 degrees C is a common annealing temperature used in industry, whereas exposure to 850 degrees C and above, the temperature typically used for conventional solar cells, requires specialized equipment. For example, processing at the higher temperature is done in some form of a diffusion furnace, the interior of which needs to be fabricated from quartz or other very high-temperature compatible materials like silicon carbide. Natcore’s process eliminates that diffusion furnace altogether.

An independent study had earlier shown that Natcore’s black silicon process should save 23.5% in manufacturing costs by eliminating one furnace from the production process. Combining that black silicon process with Natcore’s highly specialized laser processing will eliminate this second, final furnace, cutting costs yet again.

There are other benefits from low-temperature processing as well.

Eliminating exposures to elevated temperatures preserves the “minority carrier lifetime” of a cell. Maintaining high minority carrier lifetimes means that efficiencies comparable to the efficiencies of cells made with more expensive computer-chip-grade silicon can be achieved with lower-quality and lower-cost solar grade silicon. That, coupled with eliminating the use of high-temperature processing equipment, should enable these efficiencies while also reducing the costs of fabrication.

As their process is refined, say Natcore scientists, a laser-processed cell will significantly increase power output of solar cells while further reducing manufacturing costs. In their latest experiment, for example, the team has achieved an open-circuit voltage greater than 0.6 V, which represents meaningful progress toward their short-term goal of 0.65V. These and other performance metrics from the first cells indicate that, with further refinement, efficiencies equaling or exceeding today’s best commercial cells are achievable.

“Applying a black silicon etch is a very inexpensive antireflective process,” says Chuck Provini, Natcore’s president and CEO.  “Laser processing is also relatively low-cost, because it reduces energy and chemical costs associated with the furnace that it replaces. By combining two low-cost, low-temperature processes, Natcore is effecting a paradigm change as to how solar cells are made. We believe that our proprietary technology will be in great demand, and we will move to license it to the right partner as soon as possible.”

The next steps in the development will be to add Natcore’s black silicon antireflection control technology to the front of the cell and to move the front contacts to the back of the cell in what is called an interdigitated contact pattern.  Eliminating the front contacts will allow an additional 3% to 4% more light to enter the cell and increase its output by a comparable amount. Natcore will have a unique and proprietary position with this technology.

Statements herein other than purely historical factual information, including statements relating to revenues or profits, or Natcore’s future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in Natcore’s business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, Natcore expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact: Chuck Provini
732-576-8800
info@NatcoreSolar.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/natcore-technology-makes-first-laser-processed-all-low-temperature-solar-cell-304325015.html

(PROW) Negotiation for Funding Intended to Satisfy LOI for Acquisition by Progress Watch

Mobile Broadcasting Corp.
Kenneth D. Bland
Chief Executive Officer
ken@briken.net

(STCC) Announces 6-Month Earnings Growth With Its Q2 2014 Results

NEPTUNE, N.J., Oct. 20, 2014  — Sterling Consolidated Corp. (OTCBB:STCC), a leading supplier of hydraulic and pneumatic seals to the automotive and industrial marketplace, is announcing 6-month earnings growth as disclosed in its June 30, 2014 10Q.

Key Highlights:

• Completed acquisition of RG Sales Inc. in western Pennsylvania on April 1, 2014. This is the Company’s second acquisition since going public in February 2013.
• Revenues of $3.623 million are up $482K, or 15.4%, for the 6-months ended June 30, 2014 compared to the 6-months ended June 30, 2013.
• Operating income of $249K is up $192K, or 335%, for the 6-months ended June 30, 2014 compared to the 6-months ended June 30, 2013.
• Net income of $128K is up $125K, or 3,576%, for the 6-months ended June 30, 2014 compared to the 6-months ended June 30, 2013.

The revenue growth is primarily attributed to increase in incremental sales from the Company’s recent acquisitions of RG Sales Inc. and Superior Sales Inc. in North Carolina.

The operating income and net income growth is largely attributed to incremental sales from acquisitions coupled with reduced cost of goods sold due to more efficient purchasing.

Darren DeRosa, Chief Executive Officer of Sterling Consolidated, commented, “The first six months of 2014 has shown increased demand for 0-rings and we are beginning to see the results from our acquisitions reflected in our revenues and earnings. After becoming a public company our goal was to consolidate the highly fragmented o-ring distributor market and we continue to actively seek out attractive acquisition targets in the marketplace to meet this goal.”

To be added to the Sterling Consolidated investor email list, please email schichester@sterlingconsolidated.com with “STCC” in the subject line.

About Sterling Consolidated Corp.

Sterling Consolidated Corp., through its wholly-owned subsidiary, Sterling Seal and Supply has been a leading supplier of hydraulic and pneumatic seals to the automotive and industrial marketplace for more than 40 years. Through a combination of leveraging its logistical expertise and sophisticated, experienced management, the company intends to be an active and strategic consolidator of small- and mid-sized businesses within the highly-fragmented, multi-billion dollar seal industry. Currently serving more than 3,000 customers, Sterling offers acquisition targets a unique growth opportunity and competitive advantage through logistical expertise, strong regional branding and industry-specific distribution centers.

Forward-looking Statements

This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT: Investor Contact:
         Scott R. Chichester
         646-388-2495
         schichester@sterlingconsolidated.com

(GLDG) all Set to Start Gold Mining in Spring 2015

HOUSTON, TX / October 20, 2014 / Golden Global Corp, (OTC SEC reporting Pink: GLDG) is pleased to announce that the company has completed preparations at its McDame lease in British Columbia, Canada for the start of gold mining.

Production trial runs undertaken have gone well but also indicated that the upgrading of two pieces of heavy machinery is needed to reduce costs and maximize mining efficiency. Our placer mining permit was received from the Ministry of Energy and Mines on September 25, 2014 and barring any unforeseen circumstances we should start mining in spring next year.

Follow the link below to view the power point presentation of the latest photographs of our McDame lease showing the preparations completed. [http://www.accesswire.com/uploads/GLDG-Mcdame-presentation.pps]

CEO Robert L. Lee said, “I hasten to commend the excellent work contributed beyond the call of duty by John R. Hope, our Mining Consultant and an expert in the business. This has made it possible to confirm that we have crossed a major milestone and management will leave no stone unturned to become a revenue producing company by mid-2015. We must, however, still caution our shareholders and the public that as gold mining is a high risk business this milestone is not a reality until the gold is mined and sold profitably.”

About Golden Global Corp:

The company is a development stage junior gold mining company founded in 2009. It is presently traded on the OTC market as a Pink sheet fully reporting to the SEC. Its Trading symbol is GLDG and its website is http://www.goldenglobalcorp.com/

Safe Harbor Provision

Cautionary statement for purposes of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995: Information in this news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of the Company and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the execution and performance of contracts by the Company and its customers, suppliers and partners. Please also review Golden Global’s Forms 10-K and 10-Q for a more complete discussion of risk factors. The Company disclaims any obligation to update or revise statements contained in this news release based on new information or otherwise.

CONTACT INFORMATION

Golden Global Corp.
Houston, TX
Robert L. Lee
832 252 7720
http://www.goldenglobalcorp.com/

(SCOK) Aboveground Syngas Facility Commences Operations

PINGDINGSHAN, China, Oct. 20, 2014  — SinoCoking Coal and Coke Chemical Industries, Inc. (Nasdaq:SCOK), a producer of clean energy products located in Henan Province, today announced that as of the morning of October 18 China time its aboveground facility for the conversion of carbon dioxide into clean-burning syngas had begun operations and was producing and transporting syngas to customers in and around Pingdingshan.

The facility is currently operating at approximately 60 percent of capacity, said the company, and over the next 20 days will ramp up to its full capacity of 25,000 cubic meters of syngas per hour.

“After years of planning and months of construction, we have now moved forward into the commercial phase of our clean energy business plan,” said Chairman and CEO Mr. Jianhua Lv. “Through this plan, we are committed to becoming a leading supplier of clean energy to a wide range of industrial and residential customers in Henan Province.”

To help accelerate the company’s progress, the CEO said SinoCoking is in discussions regarding possible application of a gas compression technology that would allow the new facility to double its output of syngas to 50,000 cubic meters per hour.

The technology, he said, could possibly be implemented by the first quarter of next year.

Syngas, a clean-burning fuel, is increasingly utilized as a clean-energy alternative to burning coal. Comprised primarily of hydrogen and carbon monoxide, syngas can also be used to produce a range of widely-used industrial products such as fertilizers, solvents and assorted synthetic materials.

Gross profit margin on syngas sales at the new SinoCoking facility is expected to be between 45% and 50%, said Mr. Lv.

The CEO added that SinoCoking’s other syngas project, an underground coal gasification and carbon capture and storage facility designed to produce 60,000 cubic meters of syngas by March of next year, was expected to commence initial construction by the end of this month.

For additional information on SinoCoking, please go to http://asia-irpr.com/clients/sinocoking/

About SinoCoking

SinoCoking and Coke Chemical Industries, Inc. (www.scokchina.com), a Florida corporation, is an emerging producer of clean energy products located in Pingdingshan, Henan Province, China. The company has historically been a vertically-integrated coal and coke processor of basic and value-added coal products for steel manufacturers, power generators, and various industrial users. SinoCoking has been producing metallurgical coke since 2002, and acts as a key supplier to regional steel producers in central China. SinoCoking also produces and supplies thermal coal to its customers in central China. SinoCoking currently owns its assets and conducts its operations through its subsidiaries, Top Favour Limited and Pingdingshan Hongyuan Energy Science and Technology Development Co., Ltd., and its affiliated companies, Henan Province Pingdingshan Hongli Coal & Coke Co., Ltd., Baofeng Coking Factory, Baofeng Hongchang Coal Co., Ltd., Baofeng Hongguang Environment Protection Electricity Generating Co., Ltd., Zhonghong Energy Investment Company, Henan Hongyuan Coal Seam Gas Engineering Technology Co., Ltd., Baofeng Shuangri Coal Mining Co., Ltd., and Baofeng Xingsheng Coal Mining Co., Ltd.

For further information about SinoCoking, please refer to our periodic reports filed with the Securities and Exchange Commission.

Forward Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact: